The present invention provides active fibroblast growth factor variantsdemonstrating enhanced receptor subtype specificity. The preferred novelvariants retain binding to FGF Receptor Type 3 (FGFR3) triggeringintracellular downstream mechanisms leading to activation of a biologicalresponse. Methods of utilizing preferred FGF mutants in preparation ofmedicaments for the treatment of malignancies and skeletal disorders includingosteoporosis and enhancing fracture healing and wound healing processes areprovided.
